

Form PTO-1449
(Rev. 2-88)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

650057-533

SERIAL NO.

09/937,946

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S):
Roman/Harder/Miyata/Sato/Dameo/Okuyama

FILING DATE:

10/02/2001

GROUP

U.S. PATENT DOCUMENTS

EXAMINER'S INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
JS	WO 01/32164	10.05.2001	Japan	Abstract only	1		X

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

JS		Alonso-Galicia, M. et al., "Inhibition of 20-HETE Production Contributes to the Vascular Responses to Nitric Oxide," <u>Hypertension</u> 29:320-325 (1997)
		Alonso-Galicia, M., et al., "Contribution of 20-HETE to Vasodilator Actions of Nitric Oxide in the Cerebral Microcirculation," <u>Stroke</u> 30:2727-2734 (1999)
		Alonso-Galicia, M., et al., "20-HETE agonists and antagonists in the renal circulation," <u>Am. J. Physiol.</u> 277:F790-F796 (1999)
		Amet, Y., et al., "Cytochrome P450 4A and 2E1 Expression in Human Kidney Microsomes," <u>Biochemical Pharmacology</u> 53:765-771 (1997)
		Amet, Y., et al., "Noninvolvement of CYP2E1 in the (ω-1)-hydroxylation of Fatty Acids in Rat Kidney Microsomes," <u>Biochemical Pharmacology</u> 54:947-952 (1997)
		Amet, Y., et al., "P-450-Dependent Metabolism of Lauric Acid in Alcoholic Liver Disease: Comparison Between Rat Liver and Kidney Microsomes," <u>Alcoholism: Clinical and Experimental Research</u> 22:455-462 (1998)
		Bednar, M.M., et al., "16(R)-Hydroxy-5,8,11,14-eicosatetraenoic Acid, a New Arachidonate Metabolite in Human Polymorphonuclear Leukocytes," <u>Biochemical Pharmacology</u> 60:447-455 (2000)
		Christmas, P., et al., "Alternative Splicing Determines the Function of CYP4F3 by Switching Substrate Specificity," <u>Journal of Biological Chemistry</u> 276:38166-38172 (2001)
		Clozel, M. et al., "BQ-123, A Peptidic Endothelin ET _A Receptor Antagonist, Prevents the Early Cerebral Vasospasm Following Subarachnoid Hemorrhage After Intracisternal But Not Intravenous Injection," <u>Life Sciences</u> 52:825-834 (1993)
		Croft, K., et al., "Angiotensin II releases 20-HETE from rat renal microvessels," <u>Am. J. Physiol. Renal Physiol.</u> 279:F544-F551 (2000)
		Dahly, A.J., et al., "Chronic Anti-TGF-β Therapy Improves Blood Pressure and Renal Function in Dahl S Rats," <u>FASEB J.</u> 14:A133 (2000)
		Dahly, A.J., et al. "Chronic Anti-TGF-β Ab Therapy Reduces Proteinuria and Renal Injury in Hypertensive Rats," <u>American Society of Nephrology Renal Week</u> 11:332A (2000)
▽		Gebremedhin, D., et al., "Cat cerebral arterial smooth muscle cells express cytochrome P450 4A2 enzyme and produce the vasoconstrictor 20-HETE which enhances L-type Ca ²⁺ current," <u>Journal of Physiology</u> 507:3:771-781 (1998)

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if a citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. QBMAD1332105

Form PTO-1449

(Rev. 2-88)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

65005-1533

SERIAL NO.

09/937,946

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S)
Roman/Harder/Miyata/Sato/Dameo/Okuyama

FILING DATE:

10/02/2001

GROUP

U.S. PATENT DOCUMENTS

* EXAMINER'S INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

85		Gebremedhin, D., et al., "Production of 20-HETE and Its Role in Autoregulation of Cerebral Blood Flow," <u>Circulation Research</u> 87:60-65 (2000)
		Harder, D.R., et al., "Formation and action of a P-450 4A metabolite of arachidonic acid in cat cerebral microvessels," <u>American Physiological Society</u> 266:H2098-H2107 (1994)
		Juvela S., "Plasma endothelin concentrations after aneurysmal subarchnoid hemorrhage," <u>J. Neurosurg.</u> 92:390-400 (2000)
		Oyekan, A., et al., "Renal oxygenases: differential contribution to vasoconstriction induced by ET-1 and ANG II," <u>American Physiological Society</u> 273:R293-R300 (1997)
		Powell, P.K., et al., "Metabolism of Arachidonic Acid to 20-Hydroxy-5,8,11,14-eicosatetraenoic Acid by P450 Enzymes in Human Liver: Involvement of CYP4F2 and CYP4A11," <u>Journal of Pharmacology and Experimental Therapeutics</u> 285:1327-1336 (1998)
		Rosolowsky, M., "Metabolism of arachidonic acid by canine polymorphonuclear leukocytes synthesis of lipoxygenase and omega-oxidized metabolites," <u>Biochimica et Biophysica Acta</u> 1300:143-150 (1996)
		Seifert, V., et al., "Endothelin concentrations in patients with aneurysmal subarachnoid hemorrhage," <u>J. Neurosurg.</u> 82:55-62 (1995)
		Wang, M., et al., "Contribution of cytochrome P-450 4A1 and 4A2 to vascular 20-hydroxyeicosatetraenoic acid synthesis in rat kidneys," <u>American Physiological Society</u> 276L:F246-F253 (1999)
		Wang, M., et al., "Cytochrome P450-Derived Arachidonic Acid Metabolism in the Rat Kidney: Characterization of Selective Inhibitors," <u>The Journal of Pharmacology and Experimental Therapeutics</u> 284:966-973 (1998)
▽		Zou, A., et al., "Effects of 17-Octadecynoic Acid, a Suicide-Substrate Inhibitor of Cytochrome P450 Fatty Acid ω -Hydroxylase, on Renal Function in Rats," <u>The Journal of Pharmacology and Experimental Therapeutics</u> 268:474-481 (1994)

EXAMINER:

DATE CONSIDERED

* EXAMINER: Initial if a citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. QBMAD/332105

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Comp.	Known
1	1
2	2
3	3
4	4
5	5
6	6
7	7
8	8
9	9
10	10
11	11
12	12
13	13
14	14
15	15
16	16
17	17
18	18
19	19
20	20
21	21
22	22
23	23
24	24
25	25
26	26
27	27
28	28
29	29
30	30
31	31
32	32
33	33
34	34
35	35
36	36
37	37
38	38
39	39
40	40
41	41
42	42
43	43
44	44
45	45
46	46
47	47
48	48
49	49
50	50
51	51
52	52
53	53
54	54
55	55
56	56
57	57
58	58
59	59
60	60
61	61
62	62
63	63
64	64
65	65
66	66
67	67
68	68
69	69
70	70
71	71
72	72
73	73
74	74
75	75
76	76
77	77
78	78
79	79
80	80
81	81
82	82
83	83
84	84
85	85
86	86
87	87
88	88
89	89
90	90
91	91
92	92
93	93
94	94
95	95
96	96
97	97
98	98
99	99
100	100

(use as many sheets as necessary)

Sheet

1

of

1

Application Number

09/937.946

Filing Date

10/02/2001

First Named Inventor

Richard J. Roman

Group Art Unit

Examiner Name


Attorney Docket Number

650053.91533

FOREIGN PATENT DOCUMENTS

[illegible]

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T*
		LANGE, et al., 20-Hydroxyeicosatetraenoic acid-induced vasoconstriction and inhibition of potassium current in cerebral vascular smooth muscle is dependent on activation of protein kinase C. J Biol Chem. 1997 Oct 24;272(43):27345-52.	
		ZOU, et al., Inhibition of renal vascular 20-HETE production impairs autoregulation of renal blood flow. Am J Physiol. 1994 Feb;266(No. 2 Pt 2):F275-82.	
		MIYATA, et al., HET006, a potent and selective inhibitor of 20-HETE synthesizing enzyme. Br J Pharmacol. 2001 Jun;133(3):325-9.	

**EXAMINER
SIGNATURE**

DATE
CONSIDERED

6/29/2005

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231**

QBMAD/341497